Live · 21 Sep 2026 SPX 7,650.50 +0.17% NDX 29,644.17 +0.67% VIX 14.81 -4.08% GOLD 4,411.80 -0.30% CL 95.88 -4.41% BTC 81,228.01 -0.01%
NAS100 29,644 +0.67% S&P 7,651 +0.17% GOLD $4,412 −0.30% BTC $81,228 −0.01% VIX 14.81 −4.08% live tape · as of 05:00 UTC
The Screen · Healthcare · Medical Devices

Koninklijke Philips NV ADR logoKoninklijke Philips NV ADR

PHG · the NYSE · USD · Market cap $24.1B · 64,317 employees

Koninklijke Philips N.V.

PASS · Titan Ethical · score 70.0
24.68 USD

At the last full screen
2026-09-18

Screened 2026-09-18 · the tape above runs as of 05:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
31.4135.6949.36

What this means: price 24.68 against the desk's fair-value range, base estimate 35.69, over the last year.

Current read
Markdown ?
Screened · screened 2026-09-18
  • Trend Markdown
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical passes the values gate
Price24.68 USD
Fair value35.69
Ethical score70.0/100
Our investment reviews on this name
2026-09-09Read Markdown26.37-6.4% to today ✓
2026-08-08Read Markup25.02-1.4% to today
2026-07-02Read Markdown26.46-6.7% to today ✓

Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

Koninklijke Philips NV ADR holds its Markdown at $24.68. Consolidating, no directional conviction, held for 59 days.

As held on the ledger · 2026-09-18
PhaseMarkdown · caution
Quantitative stateConsolidating, no directional conviction, held for 59 days
Price at the screen$24.68
Valuation18.70 trailing · 12.96 forward price to earnings
Values screenPASS · score 70.0
Beta0.91
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 28.99% Below 33% Interest-bearing debt is just 29.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 1.20% Below 33% Cash held in interest-bearing accounts and securities is 1.2% of assets, under the one-third limit. Pass
Receivables 22.76% Below 49% Money owed to the company is 22.8% of assets, under the 49% limit. Pass
Revenue purity 0.47% Below 5% Only 0.5% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

What the Numbers Say It Is Worth

The Fair Value Range

31.41Conservative35.69Base case49.36Growth case 24.68Price

Fair value range in USD, drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. A 44.6% margin of safety to the base estimate.

The Street's Range
26.75Street low 29.50Street average 41.00Street high 24.68Price

Third-party analyst targets: 5 covering, consensus None. The average target sits +20% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections
$52.8$34.1$15.5TODAY5y agoPROJECTIONStreet high$41.00 +60%Our fair value$35.69 +39%Conservative$31.41 +22%Street avg$29.50 +15%

Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Philips Devices Need Growth Not Just Discounts

Picture a hospital ordering fresh scanners while revenue at the supplier slips five percent. That is the reality at Philips right now. The shares trade at a forty percent discount to our fair value and the forward multiple sits at thirteen times, yet the business shows no real momentum.

We pass for a simple reason. Revenue is shrinking, returns on equity are only eight percent and the moat is narrow. A hold rating from analysts and a thirty one dollar median target line up with the lack of conviction. Ethical checks clear, but that alone does not create an opportunity.

The main risks are execution on the turnaround and pressure on margins that already sit at five percent. Without sustained top line growth the discount may simply reflect a company treading water. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E13.0xexpensive even after accounting for its growth
Trailing P/E18.7xreasonably valued
EPS, trailing1.32
EPS, forward1.90
Revenue growth+0.5%slow but positive growth
Profit margin6.3%thin but positive margins
Return on equity10.2%a modest return on shareholder capital
FCF yield6.33%
Dividend yield383.00%
Debt to equity0.65moderate, manageable leverage
Current ratio1.26adequate liquidity, worth monitoring
Beta0.91steadier than the market
52-week range23.85 - 33.44
MoatNARROW
Market cap$24.1B
Employees64,317

The risks · The things to watch: its business and earnings are exposed to Netherlands and to currency swings.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

PHG trades on the NYSE (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-09-09 Markdown · changed $26.37 +5.4% Entry 5

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.

2026-08-08 Markup · changed $25.02 -5.4% Entry 4

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.

2026-07-18 Markdown $26.46 +0.0% Entry 3

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.

2026-07-03 Markdown $26.46 +0.0% Entry 2

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Markdown $26.46 Entry 1

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on PHG

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in PHG's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $25.73 -0.1% $1.01 $1,038 +3.8%
2 months $27.25 -5.7% $1.01 $980 -2.0%
3 months $27.20 -5.5% $1.01 $982 -1.8%
6 months $26.00 -1.1% $1.01 $1,028 +2.8%
1 year $22.94 +12.1% $1.01 $1,165 +16.5%
2 years $24.32 +5.7% $1.98 $1,138 +13.8%
3 years $18.08 +42.1% $1.98 $1,531 +53.1%
5 years $50.21 -48.8% $2.94 $571 -42.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever PHG does next, these words stay.

Koninklijke Philips NV ADR · PHG · Markdown · $24.68
Recorded 2026-09-18 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.